Advertisement
Mayo Clinic Proceedings Home

Simvastatin vs Therapeutic Lifestyle Changes and Supplements: Randomized Primary Prevention Trial

      OBJECTIVE

      To compare the lipid-lowering effects of an alternative regimen (lifestyle changes, red yeast rice, and fish oil) with astandard dose of a 3-hydroxy-3-methylglutaryl coenzyme A reduc-tase inhibitor (statin).

      PATIENTS AND METHODS

      This randomized trial enrolled 74 patients with hypercholesterolemia who met Adult Treatment Panel III criteria for primary prevention using statin therapy. All participants were randomized to an alternative treatment group (AG) or to receive simvastatin (40 mg/d) in this open-label trial conducted between April 1, 2006, and June 30, 2006. The alternative treatment included therapeutic lifestyle changes, ingestion of red yeast rice, and fish oil supplements for 12 weeks. The simvastatin group received medication and traditional counseling. The primary outcome measure was the percentage change in low-density lipoprotein cholesterol (LDL-C). Secondary measures were changes in other lipoproteins and weight loss.

      RESULTS

      There was a statistically significant reduction in LDL-C levels in both the AG (-42.4%±15%) (P<.001) and the simvastatin group (-39.6%±20%) (P<.001). No significant differences were noted between groups. The AG also demonstrated significant reductions in triglycerides (-29% vs -9.3%; 95% confidence interval, -61 to -11.7; P=.003) and weight (-5.5% vs -0.4%; 95% confidence interval, -5.5 to -3.4; P<.001) compared with the simvastatin group.

      CONCLUSION

      Lifestyle changes combined with ingestion of red yeast rice and fish oil reduced LDL-C in proportions similar to standard therapy with simvastatin. Pending confirmation in larger trials, this multifactorial, alternative approach to lipid lowering has promise for a subset of patients unwilling or unable to take statins.
      Trial Registration: clinicaltrials.gov identifier: NCT0042
      AG (alternative treatment group), CI (confidence interval), CK (creatine kinase), HDL-C (high-density lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol), RYR (red yeast rice), TC (total cholesterol), TG (triglycerides)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
        Lancet. 2002; 360: 7-22
        • Kashani A
        • Phillips CO
        • Foody JM
        • et al.
        Risks associated with statin therapy: a systematic overview of randomized clinical trials.
        Circulation. 2006 Dec 19; 114 (Epub 2006 Dec 11.): 2788-2797
        • Avorn J
        • Monette J
        • Lacour A
        • et al.
        Persistence of use of lipid-lowering medications: a cross-national study.
        JAMA. 1998; 279: 1458-1462
        • Simons LA
        • Levis G
        • Simons J
        Apparent discontinuation rates in patients prescribed lipid-lowering drugs.
        Med J Aust. 1996; 164: 208-211
        • Braunstein JB
        • Cheng A
        • Cohn G
        • Aggarwal M
        • Nass CM
        • Blumenthal RS
        Lipid disorders: justification of methods and goals of treatment.
        Chest. 2001; 120: 979-988
        • Dalen JE
        “Conventional” and “unconventional” medicine: can they be integrated [editorial]?.
        Arch Intern Med. 1998; 158: 2179-2181
        • Kessler RC
        • Davis RB
        • Foster DF
        • et al.
        Long-term trends in the use of complementary and alternative medical therapies in the United States.
        Ann Intern Med. 2001; 135: 262-268
        • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
        JAMA. 2001; 285: 2486-2497
        • Barnes PM
        • Powell-Griner E
        • McFann K
        • Nahin RL
        Complementary and alternative medicine use among adults: United States, 2002.
        Adv Data. 2004 May 27; 343: 1-19
        • Berthold HK
        • Unverdorben S
        • Degenhardt R
        • Bulitta M
        • Gouni-Berthold I
        Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
        JAMA. 2006; 295: 2262-2269
        • Knox J
        • Gaster B
        Dietary supplements for the prevention and treatment of coronary artery disease.
        J Altern Complement Med. 2007; 13: 83-95
        • Szapary PO
        • Wolfe ML
        • Bloedon LT
        • et al.
        Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.
        JAMA. 2003; 290: 765-772
        • Praca JM
        • Thomaz A
        • Caramelli B
        Eggplant (Solanum melongena) extract does not alter serum lipid levels.
        Arq Bras Cardiol. 2004 Mar; 82 (Epub 2004 Apr 5.): 269-276
        • Caron MF
        • White CM
        Evaluation of the antihyperlipidemic properties of dietary supplements.
        Pharmacotherapy. 2001; 21: 481-487
        • Ulbricht C
        • Basch E
        • Szapary P
        • et al.
        Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration.
        Complement Ther Med. 2005 Dec; 13 (Epub 2005 Sep 23.): 279-290
        • Bradford RH
        • Shear CL
        • Chremos AN
        • et al.
        Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up.
        Am J Cardiol. 1994; 74: 667-673
        • Marchioli R
        • Barzi F
        • Bomba E
        • GISSI-Prevenzione Investigators
        • et al.
        Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.
        Circulation. 2002; 105: 1897-1903
        • Lee JH
        • O'Keefe JH
        • Lavie CJ
        • Marchioli R
        • Harris WS
        Omega-3 fatty acids for cardioprotection.
        Mayo Clin Proc. 2008; 83: 324-332
        • Brouwer IA
        • Zock PL
        • Camm AJ
        • SOFA Study Group
        • et al.
        Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial.
        JAMA. 2006; 295: 2613-2619
        • Bays HE
        Safety considerations with omega-3 fatty acid therapy.
        Am J Cardiol. 2007 Mar 19; 99 (Epub 2006 Nov 28.): 35C-43C
        • Harris WS
        Expert opinion: omega-3 fatty acids and bleeding—cause for concern?.
        Am J Cardiol. 2007 Mar 19; 99 (Epub 2006 Nov 29.): 44C-46C
        • Harris WS
        • Bulchandani D
        Why do omega-3 fatty acids lower serum triglycerides?.
        Curr Opin Lipidol. 2006; 17: 387-393
        • Tuomilehto J
        • Lindström J
        • Eriksson JG
        • Finnish Diabetes Prevention Study Group
        • et al.
        Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
        N Engl J Med. 2001; 344: 1343-1350
        • Trichopoulou A
        • Orfanos P
        • Norat T
        • et al.
        Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study.
        BMJ. 2005 Apr 30; 330 (Epub 2005 Apr 8.): 991
        • de Lorgeril M
        • Salen P
        • Martin JL
        • Monjaud I
        • Delaye J
        • Mamelle N
        Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.
        Circulation. 1999; 99: 779-785
        • Gielen S
        • Schuler G
        • Hambrecht R
        Exercise training in coronary artery disease and coronary vasomotion.
        Circulation. 2001; 103: E1-E6
        • Himeno E
        • Nishino K
        • Okazaki T
        • Nanri H
        • Ikeda M
        A weight reduction and weight maintenance program with long-lasting improvement in left ventricular mass and blood pressure.
        Am J Hypertens. 1999; 12: 682-690
        • Sartorio A
        • Lafortuna CL
        • Marinone PG
        • Tavani A
        • La Vecchia C
        • Bosetti C
        Short-term effects of two integrated, non-pharmacological body weight reduction programs on coronary heart disease risk factors in young obese patients.
        Diabetes Nutr Metab. 2003; 16: 262-265
        • Sarafidis PA
        • Kanaki AI
        • Lasaridis AN
        Statins and blood pressure: is there an effect or not?.
        J Clin Hypertens (Greenwich). 2007; 9: 460-467
        • Schiff HB
        • MacSearraigh ET
        • Kallmeyer JC
        Myoglobinuria, rhabdomyolysis and marathon running.
        Q J Med. 1978; 47: 463-472
        • Thompson PD
        • Gadaleta PA
        • Yurgalevitch S
        • Cullinane E
        • Herbert PN
        Effects of exercise and lovastatin on serum creatine kinase activity.
        Metabolism. 1991; 40: 1333-1336
        • Thompson PD
        • Zmuda JM
        • Domalik LJ
        • Zimet RJ
        • Staggers J
        • Guyton JR
        Lovastatin increases exercise-induced skeletal muscle injury.
        Metabolism. 1997; 46: 1206-1210
        • Lefevre M
        • Champagne CM
        • Tulley RT
        • Rood JC
        • Most MM
        Individual variability in cardiovascular disease risk factor responses to low-fat and low-saturated-fat diets in men: body mass index, adiposity, and insulin resistance predict changes in LDL cholesterol.
        Am J Clin Nutr. 2005; 82: 957-963
        • Berglund L
        • Oliver EH
        • Fontanez N
        • et al.
        HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects.
        Am J Clin Nutr. 1999; 70: 992-1000
        • Hsia SH
        • Pan D
        • Berookim P
        • Lee ML
        A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease.
        Am J Cardiol. 2006 Oct 15; 98 (Epub 2006 Aug 28.): 1047-1052
        • Frontini MG
        • Srinivasan SR
        • Xu JH
        • Tang R
        • Bond MG
        • Berenson G
        Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study).
        Am J Cardiol. 2007 Jul 1; 100 (Epub 2007 May 11.): 64-68
        • Real JT
        • Chaves FJ
        • Martínez-Usó I
        • García-García AB
        • Ascaso JF
        • Carmena R
        Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia.
        Eur Heart J. 2001; 22: 465-471
        • Schmidt-Trucksäss
        Effects of exercise on plasma lipoproteins [letter].
        N Engl J Med. 2003; 348: 1494-1496
        • Kraus WE
        • Houmard JA
        • Duscha BD
        • et al.
        Effects of the amount and intensity of exercise on plasma lipoproteins.
        N Engl J Med. 2002; 347: 1483-1492
        • Dansinger ML
        • Gleason JA
        • Griffith JL
        • Selker HP
        • Schaefer EJ
        Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial.
        JAMA. 2005; 293: 43-53
        • Moore RJ
        Letter to Sonia Rodriguez, Mason Viamins. May 5, 2001. US Department of Health and Human Services Web site.
        (Accessed May 20, 2008.)
        • Heber D
        • Lembertas A
        • Lu QY
        • Bowerman S
        • Go VL
        An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents.
        J Altern Complement Med. 2001; 7: 133-139
        • Corsini A
        • Ferri N
        • Cortellaro M
        Are pleiotropic effects of statins real?.
        Vasc Health Risk Manag. 2007; 3: 611-613
        • Davignon J
        Cardioprotective and other emerging effects of statins.
        Int J Clin Pract Suppl. 2004 Oct; 143: 49-57
        • Kastelein JJ
        • Akdim F
        • Stroes ES
        • ENHANCE Investigators
        • et al.
        Simvastatin with or without ezetimibe in familial hypercholesterolemia.
        N Engl J Med. 2008 Apr 3; 358 (Epub 2008 Mar 30.): 1431-1443